Search results for " tumour"

showing 10 items of 178 documents

Vergleich von Malignitätskriterien in B-Scan- und Farbduplexsonographie mit dem histologischen Erscheinungsbild am Beispiel des experimentell induzie…

2005

BACKGROUND Malignant tumours of the head and the neck are characterised by typical signs of malignancy in greyscale- and colour-coded sonography. Sometimes, such criteria cannot be verified, and in such cases it remains unclear whether typical changes do not exist or whether we just cannot detect them with our high-end ultrasound units. We therefore compared our sonographical findings with the histology obtained in experimentally induced tumours. METHODS Experimental squamous cell carcinoma was induced subcutaneously in nude mice (n = 18), using four different cell lines. Ultrasound examination of the tumours was performed after 98 and 112 days, respectively, Central necrosis, rupture of th…

CD31Pathologymedicine.medical_specialtyNecrosisbusiness.industryUltrasoundCapsuleHistologySmall tumoursMalignancymedicine.diseasePeripheral Blood VesselmedicineRadiology Nuclear Medicine and imagingmedicine.symptombusinessUltraschall in der Medizin - European Journal of Ultrasound
researchProduct

Accurate classification of childhood brain tumours by in vivo H-1 MRS - A multi-centre study

2013

Aims: To evaluate the accuracy of single-voxel Magnetic Resonance Spectroscopy (1H-MRS) as a non-invasive diagnostic aid for pediatric brain tumours in a multi-national study. Our hypotheses are (1) that automated classification based on 1H-MRS provides an accurate non-invasive diagnosis in multi-centre datasets and (2) using a protocol which increases the metabolite information improves the diagnostic accuracy. Methods: 78 patients under 16 years old with histologically proven brain tumours from 10 international centres were investigated. Discrimination of 29 medulloblastomas, 11 ependymomas and 38 pilocytic astrocytomas was evaluated. Single-voxel MRS was undertaken prior to diagnosis (1.…

Cancer ResearchPathologymedicine.medical_specialtyClinical assessmentPilocytic AstrocytomasDiagnostic accuracyDiagnostic aidIn vivo1H MRSPattern recognitionNon-invasive diagnosismedicineMulti centrePre-surgery diagnosis assessmentbusiness.industryEcho timeLinear discriminant analysisClassificationTranslational research Tissue engineering and pathology [ONCOL 3]Multi-centre studyOncologyFISICA APLICADAFeature extractionPaediatric brain tumoursStimulated echoNuclear medicinebusinessEuropean Journal of Cancer
researchProduct

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer

2007

Paclitaxel plays an important role in the treatment of primary breast cancer. However, a substantial proportion of patients treated with paclitaxel does not appear to derive any benefit from this therapy. We performed a prospective study using tumour cells isolated from 50 primary breast carcinomas. Sensitivity of primary tumour cells to paclitaxel was determined in a clinically relevant range of concentrations (0.85-27.2 microg ml(-1) paclitaxel) using an ATP assay. Chemosensitivity data were used to study a possible association with immunohistochemically determined oestrogen and progesterone receptor (ER and PR) status, as well as histopathological parameters. Progesterone receptor (PR) m…

Cancer Researchmedicine.medical_specialtyReceptor StatusPaclitaxelmedicine.medical_treatmentBreast Neoplasmsprogesterone receptorchemistry.chemical_compoundBreast cancerInternal medicineProgesterone receptormedicineHumansRNA Messengerprimary tumour cellsChemotherapyBase SequenceDose-Response Relationship Drugbusiness.industryAntineoplastic AgentsPhytogenic/therapeutic use/Base Sequence/Breast Neoplasms/Pathology/DNA Probes/Dose-Response RelationshipDrug/Drug ResistanceNeoplasm/Humans/Immunohistochemistry/Paclitaxel/RNAMessenger/genetics/ReceptorsProgesterone/physiologyindividualized chemotherapymedicine.diseaseAntineoplastic Agents PhytogenicImmunohistochemistryIn vitrochemosensitivityEndocrinologyOncologyPaclitaxelchemistryDrug Resistance NeoplasmCancer researchImmunohistochemistryTranslational TherapeuticsDNA ProbesReceptors ProgesteroneBreast carcinomabusinessBritish Journal of Cancer
researchProduct

Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5

2015

Abstract Background This work presents relative survival estimates regarding urinary tract tumours among adult patients (age ⩾ 15 years) diagnosed in Europe. It reports on survival estimates of cases diagnosed in 2000–2007, and on survival time trends from 1999–2001 to 2005–2007. Methods Data on 677,340 adult urinary tract tumour patients, (429,154 cases of invasive and non-invasive bladder and 248,186 cases of invasive kidney cancers) diagnosed between 2000 and 2007 were provided by 86 population-based cancer registries from 29 European countries. The complete approach was used to estimate survival in 2000–2007; the period approach was used to estimate survival over time. Results The age-s…

Cancer Researchmedicine.medical_specialtyUrinary systemPopulationPopulation-based cancer registrieInternal medicineMedicineeducationGynecologyeducation.field_of_studyUrinary bladderRelative survivalbusiness.industryUrinary bladder tumoursCancer survival; EUROCARE; Kidney cancer; Population-based cancer registries; Urinary bladder tumoursCancerCancer survivalKidney cancermedicine.diseaseCancer survivalPopulation based studymedicine.anatomical_structureOncologybusinessKidney cancerEUROCARE
researchProduct

Biodistribution, Uptake and Effects Caused by Cancer-derived Extracellular Vesicles

2015

Extracellular vesicles (EVs) have recently emerged as important mediators of intercellular communication. They are released in the extracellular space by a variety of normal and cancerous cell types and have been found in all human body fluids. Cancer-derived EVs have been shown to carry lipids, proteins, mRNAs, non-coding and structural RNAs and even extra-chromosomal DNA, which can be taken up by recipient cells and trigger diverse physiological and pathological responses. An increasing body of evidence suggests that cancer-derived EVs mediate paracrine signalling between cancer cells. This leads to the increased invasiveness, proliferation rate and chemoresistance, as well as the acquisi…

Cell typeStromal cellimmunosuppressionAngiogenesisBiochemistry (medical)Clinical BiochemistryReview ArticleBiologyExtracellular vesiclesmetastatic nichelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Cell biologyExtracellular vesicles; biodistribution; trafficking; tumour microenvironment; immunosuppression; metastatic nicheParacrine signallingCancer stem celltraffickingCancer cellExtracellulartumour microenvironmentReprogrammingbiodistributiontraffick‐ ingJournal of Circulating Biomarkers
researchProduct

C1q secreted in the tumour microenvironment promotes tumour growth in the absence of complement activation

2012

We have recently shown that locally secreted C1q is involved in trophoblast invasion of decidua during pregnancy (Agostinis et al., J. Immunol. 2010;185;4420–4429). Since this physiologic process resembles to some extent tumor progression, we sought to investigate if C1q plays a similar role in tumor development and progression. Immunohistochemical analysis of several solid tumours including colon, prostate, lung and breast cancer and melanoma revealed the presence of C1q that was localized on the vascular endothelium and also distributed in the stroma in the absence of C4. To investigate the in vivo role of C1q in tumour development, 6/8 week old female WT and C1q−/− C57BL/6 mice received …

ChemistrytumourImmunologyImmunology and AllergycomplementHematologycomplement; tumourComplement systemComplement (complexity)Cell biology
researchProduct

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour

2014

Abstract Background To explore the activity of pazopanib in solitary fibrous tumour (SFT). Patients and methods In a preclinical study, we compared the activity of pazopanib, sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT) xenotransplanted into Severe Combined Immunodeficiency (SCID) mice. Antiangiogenics were administered at their reported optimal doses when mean tumour volume (TV) was 80 mm3. Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012, six consecutive patients with advanced SFT received pazopanib, on a national name-based programme. In one case sunitinib was administered after pazopanib failure. Results In the …

Chemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sulfonamides; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2; Cancer Research; Oncology; Medicine (all)OncologyMaleCancer ResearchIndolesAxitinibPyridinesPyridinemedicine.medical_treatmentSolitary fibrous tumourAdministration OralAngiogenesis InhibitorsMice SCIDPharmacologyPyrroleAntineoplastic Agentchemistry.chemical_compoundMiceSolitary Fibrous TumorChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Cancer Research; Oncology; Medicine (all)Transplantation HeterologouMonoclonalSunitinibHumanizedSulfonamidesHeterologousSunitinibMedicine (all)ImidazolesSarcomaMiddle AgedSorafenibPlatelet-Derived Growth Factor betaAxitinibBevacizumabOncologySolitary Fibrous TumorsAdministrationAngiogenesis InhibitorHumanmedicine.drugReceptorPhenylurea CompoundSorafenibOralAdultNiacinamidemedicine.medical_specialtyIndazolesBevacizumabMAP Kinase Signaling SystemTransplantation HeterologousAntineoplastic AgentsSulfonamideAntibodies Monoclonal HumanizedSCIDAntibodiesReceptor Platelet-Derived Growth Factor betaPazopanibInternal medicineRegorafenibmedicineAnimalsHumansChemotherapyPyrrolesImidazoleTyrosine kinaseAgedChemotherapyTransplantationAnimalbusiness.industryPhenylurea CompoundsPazopanibmedicine.diseaseChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-2IndazolePyrimidinesPyrimidinechemistryIndolebusinessProgressive diseaseNeoplasm Transplantation
researchProduct

REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after …

2017

International audience

Clinical trial[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismDuodeno-pancreatic neuroendocrine tumoursMaintenance[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismComputingMilieux_MISCELLANEOUS
researchProduct

Imaging to study solid tumour origin and progression: lessons from research and clinical oncology

2017

Biomedical imaging in recent decades has clarified our understanding of normal and pathological cellular processes in vivo. In particular, this approach recently provided insights into processes occurring at a molecular or genetic level rather than at the anatomical level. The evolution of this discipline by engineering have led to its integration into biomedical research to (1) increase sensitivity and resolution imaging and to (2) improve tissue and cell specificity. Currently, imaging approaches are used in three different biomedical areas: (a) identification of cellular processes in physiological and disease state; (b) in vivo single-cell imaging; and (c) identification of new prognosti…

Diagnostic Imaging0301 basic medicineOncologymedicine.medical_specialtyPathologyeducationImmunologyBiologyMedical OncologyMultimodal Imaging03 medical and health sciences0302 clinical medicineCancer stem cellNeoplasmsInternal medicinemedicineAnimalsHumansImmunology and AllergyMolecular Targeted TherapySolid tumourClinical OncologyResearchOptical ImagingCell BiologyImaging cell biology cancer stem cellsMolecular ImagingCell Transformation Neoplastic030104 developmental biology030220 oncology & carcinogenesisDisease ProgressionNeoplastic Stem Cells
researchProduct

Cáncer en los primeros 18 meses de vida

2020

Resumen: Introducción: La enfermedad oncohematológica continúa siendo la primera causa de mortalidad no traumática en la infancia y una importante causa de morbilidad. El paciente menor de 18 meses presenta particularidades clínicas, diagnósticas y terapéuticas que es interesante conocer por todo pediatra, con el fin de lograr una mayor supervivencia y una menor comorbilidad a lo largo de su vida. Material y métodos: Estudio descriptivo retrospectivo de variables clínicas, diagnósticas y terapéuticas en pacientes menores de 18 meses diagnosticados de enfermedad oncohematológica que reciben quimioterapia en una unidad de oncología pediátrica entre enero 2007 y agosto 2019. Resultados: Setent…

Early infancyLife-threatening symptoms03 medical and health sciences0302 clinical medicineToxicity030225 pediatricsPediatrics Perinatology and Child HealthChemotherapyChemotherapy Early infancy Embryonic tumours Life-threatening symptoms Primera infancia Quimioterapia Síntomas amenazantes para la vida Toxicidad Toxicity Tumores embrionariosEmbryonic tumoursPediatricsRJ1-570Anales de Pediatría
researchProduct